The world's most common hormone condition just got a new name.
For decades, the name "Polycystic Ovary Syndrome" has caused no small amount of confusion for the millions of people trying to understand their diagnosis. Now, after 14 years of global research, consultation and advocacy, that name has officially changed.
Published in The Lancet on 12 May 2026, an international consensus has renamed the condition:
Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The new name was led by Professor Helena Teede of Monash University, meaning this landmark change has strong Australian roots. Here's what it means, why it matters, and what (if anything) changes for you.
Why Was the Name Changed?
The term "polycystic ovary syndrome" has long been criticised for being misleading and for good reason.
Despite the name, many people with PCOS don't actually have ovarian cysts. The structures seen on ultrasound are immature follicles, not true cysts. Meanwhile, some of the most significant features of the condition - insulin resistance, metabolic changes, skin symptoms and mental health impacts are nowhere to be found in the old name.
Patient advocates and researchers argued for years that "PCOS" framed a complex, whole-body condition as primarily an ovarian or fertility issue, leading to delayed diagnosis and fragmented care. Research suggests that diagnostic delays affect up to 70% of those with the condition.
The new name, Polyendocrine Metabolic Ovarian Syndrome, aims to more accurately reflect the full picture.
What Does PMOS Actually Mean?
The new terminology breaks the condition down more clearly:
- Polyendocrine — recognises that the condition involves multiple interacting hormonal systems, including insulin, androgens and neuroendocrine pathways
- Metabolic — acknowledges the links with insulin resistance, blood sugar regulation, weight changes and cardiovascular health
- Ovarian — confirms that the ovaries remain part of the picture when it comes to symptoms and diagnosis
The change wasn't made lightly. It followed what researchers described as "an unprecedented, rigorous, multistep global consensus process" involving 56 international academic, clinical and patient organisations. More than 22,000 health professionals and people living with the condition participated in surveys and workshops across multiple world regions and 85.6% of patients and 76.1% of health professionals agreed with the change.
Will Your Diagnosis or Treatment Change?
Not right now. The diagnostic criteria themselves are not changing and if you already have a PCOS diagnosis, the symptoms, testing processes and treatment approaches remain largely the same.
The change is primarily about improving how the condition is understood, communicated and researched. A three-year transition plan is underway, with the new terminology expected to be formally incorporated into the International Guideline, used across 195 countries, when it is updated in 2028.
In the meantime, you'll see both names used side by side as healthcare providers, researchers and organisations adapt.
Experts hope that better terminology will lead to:
- Earlier and more accurate diagnosis
- More holistic treatment that addresses metabolic and mental health, not just reproductive symptoms
- Reduced stigma and confusion
- Greater research funding
- Improved education for healthcare providers
Why This Matters for People Living With PCOS/PMOS
Many people have shared that the old name made it difficult to explain their condition - or even understand it themselves. Some felt dismissed because they didn't have ovarian cysts. Others found the name focused too narrowly on fertility, even when their most pressing symptoms involved energy, skin, mood, metabolism or weight.
The renaming is about more than semantics. It reflects a shift in how medicine understands this condition: not as an ovarian disorder, but as a complex, long-term hormonal and metabolic condition that affects more than 170 million people worldwide. That's around 1 in 8 women!
For many, that recognition is long overdue.
It's also worth noting that not everyone in the community supports the change. Some long-time advocates have raised concerns about losing the visibility and community that the "PCOS" name has built over decades — a fair point, and one the researchers have acknowledged as part of the transition process.
An Australian-Led Change
It's worth highlighting that this global effort was led here in Australia. Professor Helena Teede, Director of Monash University's Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, led the 14-year name change process alongside an international team and 56 patient and professional organisations.
This world-leading women's health research in our own backyard is something to be proud of.
The Bottom Line
PCOS becoming PMOS may look like a small change on paper, but it represents a meaningful shift in how this condition is understood globally. It acknowledges the hormonal, metabolic and psychological dimensions that the old name obscured and for the people living with it, that recognition matters.
As awareness grows and the transition takes effect, the hope is that more people will receive earlier diagnosis, more comprehensive support and care that better reflects their full experience.
Read the full research paper: Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process — The Lancet, May 2026
Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for an accurate diagnosis and appropriate treatment.
www.linkedin.com/in/brenda-tootell
